Tag: Gatsby trial
Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial
Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...
- About
- Articles
- ADC Directory
- Resources
- ADC Drug Map
- Resources for Clinicians
- ADC University
- Recommended Reading
- ADC Review | The Bookstore
- ADC Review | The Bookstore – Lyophilization of Pharmaceuticals and Biologicals
- ADC Review | The Bookstore – Bioconjugation: Methods and Protocols
- ADC Review | The Bookstore – Biopharmaceutical Processing: Development, Design, and Implementation of Manufacturing Processes
- ADC Review | The Bookstore – Analytical Characterization of Biotherapeutics
- ADC Review | The Bookstore – Antibody Drug Discovery | Molecular Medicine and Medicinal Chemistry
- ADC Review | The Bookstore – Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)
- ADC Review | The Bookstore – Antibody-Drug Conjugates Methods in Molecular Biology
- ADC Review | The Bookstore – Innovations for Next-Generation Antibody-Drug Conjugates
- ADC Review | The Bookstore – Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer 1st Edition
- ADC Review | The Bookstore – Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications
- ADC Review | The Bookstore – Antibody-Drug Conjugates: Methods and Protocols (Methods in Molecular Biology) 1st ed. 2020 Edition
- ADC Review | The Bookstore – Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer
- ADC Review | The Bookstore – Cytotoxic Payloads for Antibody–Drug Conjugates
- ADC Review | The Bookstore – Innovations for Next-Generation Antibody-Drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.